SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that it will be presenting at two upcoming Keystone Symposia. Details are as follows:
January 6-11, 2006: Lymphocyte Activation and Signaling (A1) in Steamboat Springs, Colorado Presentation Time: Saturday, January 7 Poster Number: 117 Title: “R406/788, a Potent and Selective Syk kinase Inhibitor for the Treatment of Rheumatoid Arthritis” January 21-26, 2006: Adipogenesis, Obesity and Inflammation in Vancouver, British Columbia Presentation Time: Tuesday, January 24 Poster Number: 340 Title: “Functional studies of adiponectin receptor AdipoR1 and AdipoR2" About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in allergy/asthma, rheumatoid arthritis and cancer.
This press release contains “forward-looking” statements, including statements related to Rigel’s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “plans,” “intends,” “expects” and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel’s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel’s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward- looking statements.
Contact: Raul Rodriguez of Rigel, +1-650-624-1302, or invrel@rigel.com; or Carolyn Bumgardner Wang of WeissComm Partners, Inc., +1-415-946-1065, or carolyn@weisscommpartners.com, for Rigel.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comRigel Pharmaceuticals, Inc.
CONTACT: Raul Rodriguez of Rigel, +1-650-624-1302, or invrel@rigel.com; orCarolyn Bumgardner Wang of WeissComm Partners, Inc., +1-415-946-1065, orcarolyn@weisscommpartners.com, for Rigel
Web site: http://www.rigel.com//
